Table 3.
Stroke subjects (n = 12) | Controls | |||
---|---|---|---|---|
Hemiparetic | Nonparetic | IGT (n = 12) | NGT (n = 12) | |
Overall CD (cap/mm2) | 207 ± 12§,‡ | 252 ± 22 | 242 ± 10† | 295 ± 11 |
Type I | 203 ± 18*,‡ | 229 ± 23† | 241 ± 10† | 302 ± 12 |
Type IIa | 216 ± 18*,‡ | 283 ± 21‖ | 232 ± 31† | 276 ± 41 |
Type IIx | 212 ± 20*,† | 302 ± 34 | 273 ± 21 | 290 ± 29 |
Overall CFPE (cap/mm) | 3.45 ± 0.17§,‖,‡ | 4.50 ± 0.22† | 4.29 ± 0.14‡ | 5.05 ± 0.15 |
Type I | 3.69 ± 0.17§,‖,‡ | 4.58 ± 0.20† | 4.63 ± 0.15‡ | 5.34 ± 0.19 |
Type IIa | 3.42 ± 0.17§,‖,‡ | 4.49 ± 0.27 | 3.97 ± 0.16‡ | 4.71 ± 0.16 |
Type IIx | 3.07 ± 0.18*,‖,† | 4.06 ± 0.36 | 3.57 ± 0.26 | 4.08 ± 0.13 |
Data are presented as mean±SEM.
Significant difference, compared to nonparetic leg muscle (*P <0.05, §P <0.001);
significant difference, compared to IGT control muscle (P <0.05);
significant difference, compared to NGT control muscle (†P <0.05, ‡P <0.01).